Endpoint dilution using an antibody to the adenoviral hexon protein may be used to quantitate virus production or infection efficiency of target cells (Armentano et al. (1995) Hum. Gene Ther. 6:1343-53.

In addition to containing the DNA sequences encoding one or more transgenes, the chimeric adenoviral vectors of the invention may contain any expression control sequences such as a promoter or enhancer, a polyadenylation element, and any other regulatory elements that may be used to modulate or increase expression, all of which are operably linked in order to allow expression of the transgene. The use of any expression control sequences, or regulatory elements, which facilitate expression of the transgene is within the scope of the invention. Such sequences or elements may be capable of generating tissue-specific expression or be susceptible to induction by exogenous agents or stimuli.

## Construction of Retroviral Vectors

15

5

10

The antigen presenting cells described herein can also be genetically modified with retroviral vectors produced recombinantly by procedures already taught in the art. For example, WO 94/29438 describes the construction of retroviral packaging plasmids and packaging cell lines. As is apparent to the skilled artisan, the retroviral vectors useful in the methods of this invention are capable of infecting the cells described herein. The techniques used to construct vectors, and transfect and infect cells are widely practiced in the art. Examples of retroviral vectors are those derived from murine, avian or primate retroviruses. Retroviral vectors based on the Moloney murine leukemia virus (MoMLV) are the most commonly used because of the availability of retroviral variants that efficiently infect human cells. Other suitable vectors include those based on the Gibbon Ape Leukemia Virus (GALV) or HIV.

25

30

20

The range of host cells that may be infected by a retrovirus or retroviral vector is determined by the viral envelope protein. The recombinant virus can be used to infect virtually any other cell type recognized by the env protein provided by the packaging cell, resulting in the integration of the viral genome in the

transduced cell and the stable production of the foreign gene product. In general, murine ecotropic env of MoMLV allows infection of rodent cells, whereas amphotropic env allows infection of rodent, avian and some primate cells, including human cells. Amphotropic packaging cell lines for use with MoMLV systems are known in the art and commercially available and include, but are not limited to, PA12 and PA317. Miller et al. (1985) Mol. Cell. Biol. 5:431-437; Miller et al. (1986) Mol. Cell. Biol. 6:2895-2902; and Danos et al. (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464. Xenotropic vector systems exist which also allow infection of human cells.

10

5

The host range of retroviral vectors has been altered by substituting the env protein of the base virus with that of a second virus. The resulting, "pseudotyped", virus has the host range of the virus donating the envelope protein and expressed by the packaging cell line. Recently, the G-glycoprotein from vesicular stomatitis virus (VSV-G) has been substituted for the MoMLV env protein. Burns et al. (1993) Proc. Natl. Acad. Sci USA 90:8033-8037; and PCT patent application WO 92/14829. Since infection is not dependent on a specific receptor, VSV-G pseudotyped vectors have a broad host range.

Usually, the vectors will contain at least two heterologous genes or gene

sequences: (i) the therapeutic gene to be transferred; and (ii) a marker gene that

enables tracking of infected cells.

20

15

The viral vector can be modified to incorporate chimeric envelope proteins or nonviral membrane proteins into retroviral particles to improve particle stability and expand the host range or to permit cell type-specific targeting during infection. The production of retroviral vectors that have altered host range is taught, for example, in WO 92/14829 and WO 93/14188. Retroviral vectors that can target specific cell types in vivo are also taught, for example, in Kasahara et al. (1994) Science 266:1373-1376. Kasahara et al. describe the construction of a Moloney leukemia virus (MoMLV) having a chimeric envelope protein consisting of human erythropoietin (EPO) fused with the viral envelope protein. This hybrid virus shows tissue tropism for human red blood progenitor cells that bear the

30

receptor for EPO, and is therefore useful in gene therapy of sickle cell anemia and thalassemia. Retroviral vectors capable of specifically targeting infection of cells are preferred for *in vivo* gene therapy.

5

10

15

20

25

The vector construct is introduced into a packaging cell line which will generate infectious virions. Packaging cell lines capable of generating high titers of replication-defective recombinant viruses are known in the art, see for example, WO 94/29438. Viral particles are harvested from the cell supernatant and purified for *in vivo* infection using methods known in the art such as by filtration of supernatants 48 hours post transfection. The viral titer is determined by infection of a constant number of appropriate cells (depending on the retrovirus) with titrations of viral supernatants. The transduction efficiency can be assayed 48 hours later by a variety of methods, including Southern blotting.

After viral transduction, the presence of the viral vector in the transduced cells or their progeny can be verified such as by PCR. PCR can be performed to detect the marker gene or other virally transduced sequences. Generally, periodic blood samples are taken and PCR conveniently performed using e.g. NeoR probes if the NeoR gene is used as marker. The presence of virally transduced sequences in bone marrow cells or mature hematopoietic cells is evidence of successful reconstitution by the transduced cells. PCR techniques and reagents are well known in the art, See, generally, PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS. Innis, Gelfand, Sninsky & White, eds. (Academic Press, Inc., San Diego, 1990) and commercially available (Perkin-Elmer).

In vitro/ex vivo, exposure of human DCs to adenovirus (Ad) vector at a multiplicity of infection (MOI) of 500 for 16-24 h in a minimal volume of scrumfree medium reliably gives rise to transgene expression in 90-100% of DCs. The efficiency of transduction of DCs or other APCs can be assessed by immunofluorescence using fluorescent antibodies specific for the tumor antigen being expressed (Kim et al., 1997). Alternatively, the antibodies can be conjugated to an enzyme (e.g. HRP) giving rise to a colored product upon reaction

with the substrate. The actual amount of antigen being expressed by the APCs can be evaluated by ELISA.

Transduced APCs can subsequently be administered to the host via an intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.

5

10

15

20

25

In vivo transduction of DCs, or other APCs, can potentially be accomplished by administration of Ad (or other viral vectors) via different routes including intravenous, intramuscular, intranasal, intraperitoneal or cutaneous delivery. The preferred method is cutaneous delivery of Ad vector at multiple sites using a total dose of approximately 1x10<sup>10</sup>-1x 10<sup>12</sup> i.u. Levels of in vivo transduction can be roughly assessed by co-staining with antibodies directed against APC marker(s) and the TAA being expressed. The staining procedure can be carried out on biopsy samples from the site of administration or on cells from draining lymph nodes or other organs where APCs (in particular DCs) may have migrated. The amount of TAA being expressed at the site of injection or in other organs where transduced APCs may have migrated can be evaluated by ELISA on tissue homogenates.

Although viral gene delivery is more efficient, DCs can also be transduced in vitro/ex vivo by non-viral gene delivery methods such as electroporation, calcium phosphate precipitation or cationic lipid/plasmid DNA complexes.

Transduced APCs can subsequently be administered to the host via an intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.

In vivo transduction of DCs, or other APCs, can potentially be accomplished by administration of cationic lipid/plasmid DNA complexes delivered via the intravenous, intramuscular, intranasal, intraperitoneal or cutaneous route of administration. Gene gun delivery or injection of naked plasmid DNA into the skin also leads to transduction of DCs. Intramuscular delivery of plasmid DNA may also be used for immunization.

The transduction efficiency and levels of transgene expression can be assessed as described above for viral vectors.

## **Expansion of Immune Effector Cells**

5

The present invention makes use of these APCs to stimulate production of an enriched population of antigen-specific immune effector cells. The antigen-specific immune effector cells are expanded at the expense of the APCs, which die in the culture. The process by which naïve immune effector cells become educated by other cells is described essentially in Coulic (1997) Molec. Med. Today 3:261-268.

10

In a preferred embodiment, the antigen-specific immune effector cells are CTLs. In one aspect, the cytotoxic T cells are polyclonal T cells isolated from a site of cytotoxic T cell infiltration from a subject. Alternatively, such cells may be isolated from a site of cytotoxic T cell infiltration from two or more subjects or human patients, in which the subjects share an MHC halotype. In another embodiment, the CTLs may be two or more cytotoxic T cell lines. In yet another embodiment, the CTLs may be any combination of the foregoing.

15

In a further aspect of the invention, the site of cytotoxic T cell infiltration is a tumor. The tumors from which cells or cell lines are obtained can be the same type of tumor in different individuals with a shared MHC halotype or different types of tumors from different subjects who share an MHC haplotype.

20

The APCs prepared as described above are mixed with naïve immune effector cells. Preferably, the cells may be cultured in the presence of a cytokine, for example IL2. Because dendritic cells secrete potent immunostimulatory cytokines, such as IL2, it may not be necessary to add supplemental cytokines during the first and successive rounds of expansion. In any event, the culture conditions are such that the antigen-specific immune effector cells expand (i.e. proliferate) at a much higher rate than the APCs. Multiple infusions of APCs and optional cytokines can be performed to further expand the population of antigen-specific cells.

30

In one embodiment, the immune effector cells are T cells and are specific for tumor-specific antigens which are presented by the APCs.

## Compositions

5

10

This invention also provides compositions containing any of the abovementioned proteins, muteins, polypeptides, nucleic acid molecules, vectors, cells
antibodies and fragments thereof, and an acceptable solid or liquid carrier. When
the compositions are used pharmaceutically, they are combined with a
"pharmaceutically acceptable carrier" for diagnostic and therapeutic use. These
compositions also can be used for the preparation of medicaments for the
diagnosis and treatment of diseases such as cancer.

Tumor Protection in Animal Models

15

Applicants are the first to establish that, based on the animal models described below, prevaccination with the compositions of this invention will prevent or delay onset of disease.

20

w

25

The murine B16 melanoma model was used. In this model, C57BL/6 mice were immunized with bone marrow-derived DCs transduced with an Ad vector encoding either human gp100 (Ad/hugp100) or mouse gp100 (Ad/mgp100). Mice immunized against heterologous human gp100 developed a protective immune response and were resistant to a lethal subcutaneous challenge of B16 melanoma cells (syngeneic tumor cell line that expresses gp100). In contrast, mice immunized with homologous mouse gp100 failed to mount a protective immune response against B16 melanoma cells and developed tumors at the site of B16 cell injection. This finding illustrates the difficulty in breaking tolerance against a self antigen (mouse gp100). The corresponding heterologous antigen from a different species (human gp100), however, is likely to contain several Class I and Class II-associated epitopes that will be recognized as foreign and elicit CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses, respectively. The induction of cross-reactive CTLs that recognize

both the heterologous and homologous self-antigen can then lead to lysis of host tumor cells.

Unfortunately, this type of animal model cannot be used to test the efficacy of modified or heterologous tumor antigens being considered for use in humans since mice and humans recognize different epitopes, primarily as a result of differences in their MHC molecules. It may be possible, however, to use the allogeneic human peripheral blood lymphocyte - severe combined immunodeficiency mouse (Hu-PBL-SCID) model. SCID mice lack mature B and T lymphocytes and can be reconstituted with human PBLs. It may be possible to immunize such mice with test antigen to induce a response in adoptively transferred human PBLs and evaluate protection against challenge with a human tumor cell line (Mosier et al., 1988; Parney et al., 1997; Albert et al., 1997).

Another possibility is immunization of HLA-A2.1 transgenic mice to reproduce the immune reactivity of HLA-A2 individuals.

Adoptive Immunotherapy and Vaccines

5

10

15

20

25

30

The expanded populations of antigen-specific immune effector cells of the present invention find use in adoptive immunotherapy regimes and as vaccines.

Adoptive immunotherapy methods involve, in one aspect, administering to a subject a substantially pure population of educated, antigen-specific immune effector cells made by culturing naïve immune effector cells with APCs as described above. Preferably, the APCs are dendritic cells.

In one embodiment, the adoptive immunotherapy methods described herein are autologous. In this case, the APCs are made using parental cells isolated from a single subject. The expanded population also employs T cells isolated from that subject. Finally, the expanded population of antigen-specific cells is administered to the same patient.

In another embodiment, the adoptive immunotherapy methods are allogeneic. Here, cells from two or more patients are used to generate the APCs, and stimulate production of the immune effector cells. For instance, cells from

other healthy or diseased subjects can be used to generate antigen-specific cells in instances where it is not possible to obtain autologous T cells and/or dendritic cells from the subject providing the biopsy. The expanded population can be administered to any one of the subjects from whom cells were isolated, or to another subject entirely.

In a further embodiment, APCs or immune effector cells are administered with an effective amount of a stimulatory cytokine, such as IL-2 or a costimulatory molecule.

5

10

15

20

25

30

The agents identified herein as effective for their intended purpose can be administered to subjects or individuals susceptible to or at risk of developing a disease, such as cancer. When the agent is administered to a subject such as a mouse, a rat or a human patient, the agent can be added to a pharmaceutically acceptable carrier and systemically or topically administered to the subject. To determine patients that can be beneficially treated, a turnor regression can be assayed. Therapeutic amounts can be empirically determined and will vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the therapy. When delivered to an animal, the method is useful to further confirm efficacy of the agent. As an example of an animal model, groups of nude mice (Balb/c NCR nu/nu female, Simonsen, Gilroy, CA) are each subcutaneously inoculated with about 105 to about 109 hyperproliferative, cancer or target cells as defined herein. When the tumor is established, the agent is administered, for example, by subcutaneous injection around the tumor. Tumor measurements to determine reduction of tumor size are made in two dimensions using venier calipers twice a week. Other animal models may also be employed as appropriate.

Administration in vivo can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or

multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be found below.

The agents and compositions of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.

More particularly, an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including nasal, topical (including transdermal, aerosol, buccal and sublingual), parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It will also be appreciated that the preferred route will vary with the condition and age of the recipient, and the disease being treated.

The compositions and methods described herein are particularly useful in providing or inducing a prophylactic immune response in an animal. Animals in a pre-disease state or in a disease free interval, i.e., having or pre-disposed to a condition subject to immune surveillance, are most suitably treated by the methods and compositions described herein. Such conditions involve the activation of an immune response in a diseased state or period.

20

5

10

15

## Example

Dendritic cells were derived from peripheral blood of a HLA-A2+ human donor using standard GM-CSF/IL-4 culture technique. After six days, the cells were infected with an adenovirus (serotype 2) construct encoding human gp 100. At T=7 days, they were restimulated with 5 x 10<sup>5</sup> infected autologous DCs (from frozen stocks) and given 50 U/ml rhIL-2. At T=14 days, the cultures were treated with leucyl-leucyl-methyl ester in order to eliminate NK cell activity. Immediately after treatment, the cells were washed thoroughly and replated along with 1 x 10<sup>7</sup> mitomycin C-treated autologous PBMC as feeders. At T=21 days,

30

cells were split and replated at 5 x 10<sup>5</sup> cells/ml in Iscoves/10% human AB serum/1000U rhIL-2/ml. At T=26 days, the CTLs raised against gp100 were tested in <sup>51</sup>Cr-release assay using peptide pulsed T2 cells as targets. Effector CTLs were TIL 1520 which specifically recognize an HLA-A-A2 restricted epitope of the wild-type human gp100 protein. Figure 5 shows the results of this assay. There is epitope-specific recognition that was not present prior to education of the T cells with the infected DCs.

5

10

15

It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and the following examples are intended to illustrate and not limit the scope of the invention. For example, any of the above-noted compositions and/or methods can be combined with known therapies or compositions. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

## CLAIMS

1. A method of inducing a prophylactic immune response to a selfantigen in a subject, comprising administering to the subject an effective amount of the antigen or an altered form of the antigen.

5

15

20

25

30

- 2. The method of claim 1, wherein the antigen is administered as a polynucleotide coding for the self-antigen.
- 10 3. The method of claim 2, wherein the polynucleotide is delivered as naked DNA.
  - 4. The method of claim 2, wherein the polynucleotide is delivered in a gene delivery vehicle.

5. The method of claim 1, further comprising administering an effective amount of an immunostimulatory agent to the subject.

- 6. The method of claim 5, wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.
- 7. The method of claim 1, wherein the antigen is administered in an antigen presenting cell.
- 8. The method of claim 7, wherein the antigen presenting cell has been genetically modified by insertion of a polynucleotide coding for the antigen.
  - 9. The method of claim 7, wherein the antigen presenting cell is a foster antigen presenting cell, a hybrid antigen presenting cell, or a pulsed antigen presenting cell.

10. The method of claim 7, wherein the antigen presenting cell is a dendritic cell.

5

- 11. The method of claim 7, further comprising administering an effective amount of an immunostimulatory agent to the subject.
- 12. The method of claim 11, wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.

10

15

20

- 13. The method of claim 1 or 7, wherein the self-antigen is a tumor associated antigen (TAA).
- 14. A method of providing a prophylactic immune response to a selfantigen in a subject, comprising administering to the subject an effective amount of educated immune effector cells, educated to specifically recognize and lyse cells expressing the self-antigen or an altered form of the self-antigen.
- 15. The method of claim 14, wherein the immune effector cells have been produced by stimulating naïve immune effector cells with antigen presenting cells that present the antigen or an altered self-antigen to the naïve immune effector cells.
  - 16. The method of claim 14, wherein the educated immune effector cells are produced *ex vivo*.
  - 17. The method of claim 14, wherein the educated immune effector cells are produced *in vivo*.

18. The method of claim 14, further comprising administering an effective amount of an immunostimulatory agent.

- 19. The method of claim 18, wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.
- 20. The method of claim 1 or 14, wherein the subject is characterized as being in a disease-free state but genetically predisposed to a condition subject to immune surveillance.

10

15

- 21. The method of claim 20, wherein the condition is associated with the presence of the HER-2/neu gene in the subject.
- 22. The method of claim 1 or 14, wherein the subject is characterized as being in a disease free interval of a condition subject to immune surveillance.
  - 23. The method of claim 22, wherein the condition is melanoma.

4	
ر 1 1	FIG
1.8	19
FIG.	FIG.

DWLCVSROLR HLAVIGALLA VGATKVPRNQ MOLVLKRCLL -\*G-QR-SF-HUMAN MOUSE

TKAWNROL YP Λ---d----PLV-LSA--- EWTEAQRIDC WRGGQVSLKV SNDGPTLIGA NASFSIALNF PGSQKVLPDG ----4 -NS9-A--- NGSQVWGGQP VYPQETDDAC IFPDGGPCPS GSWSQKRSFV --pKpp---"""d"""" QV I WVNNT I I 01

SIGTGRAMLG THTMEVTVYH RRGSRSYVPL --- H--K--QVLGGPVSGL 2 ----YVWK TWGQYW 5

AHSSSAFTIT DQVPFSVSVS QLRALDGGNK HFLRNQPLTF ALQLHDPSGY ---H------0---E1-201

FIG. 1A SRALVVIHIY LEPGPVTAQV VLQAAIPLIS LAEADLSYTW DFGDSSGTL! ----B1 251

RECORFIED SHEET (RULE 91)

M

7	
213	515
LSGQQ VX	***

EVVGTTPGQA PTAEPSGTTS CGSSPVPGII DGHRPIAEAP NITAGQVPII

301

351

-- --YM----- G--SR-GT-- ------M --TQ-----V

VQVPTTEVIS TAPVQMPTAE STGMTPEKVP VSEVMGTTLA EMSTPEATGM --M-----TA -TSE--L-\*\* \*\*\*\*\*\*\* \*-A-ID---- -V--T-G--T

--PLLP-0-S SCTTAAQVIT TEWVETTARE LPIPEPEGPD ASSIMSTES! ----\*\*\*\*\*\*\* --- \ \---**TPAEVS!VVL** d\*\*\*\*\*\* 401

GSFSVTLDIV QGIESAEILQ TGGLGPLLDG TATLRLVKRQ VPLDCVLYRY 

ELIVSCOGGL PKEACMEISS PGCQPPAQRL CQPVLPSPAC --Q---d-S-----0----AVPSGEGDAF 501

----A---9 OLVLHQILKG GSGTYCLNVS LADTNSLAVV STQLIMPGQE AGLGQVPLIV Q---^\/\ A----A ----551

PHSSSHWLRL PRIFCSCP16 -PV-RARGL------------MKQDFSVPQL X----X---X GILLVLMAVV LASLIYRRRL 601

651 ENSPLLSGQQ V

	2 .5 .T.	40 666CACAGACGCTCC            666CACGGCCACTCT 50	00 GTCCTGGGGATTGCT                  ATCCTGGGAGTCTTA 110	60 CCTTGATGGACAAA 	0 230 GTGAGAGCCCTGAT               AAGAAGGGTTTGAT 230 240
FIG. 2A	FIG. 2B	GTTATCCCAGGAAG(	GCATCCTGATCGTGG	150 6AAGTGGATACAGAA               6AAATGGATACAGAG	CAAGATGCTCAT
FIG 2A		ACATTCACTTTG	TATGTCACTGCTGAAGAGGCCGCAGGGATCG	130 140 140   CCTGGTACTGTAGAGAC	180
	•	MMART hwart	MMART	MMART	MMART

RECTIFIED SHEET (RULE 91)

MWART hwart	240 250 250 290 290 240 280 280 290 280 280 290 280 280 290 280 280 290 280 280 280 280 280 250 280 250 250 250 250 250 280 250 280 280 280 280 280 280 280 280 280 28
MWART HWART	300 340 340 CCGCCTATGAGAAGCTCTCT————————————————————
D MWART	MPQEDIHF — GYPRKGHRRSYVTAEEAAGIGILIVVLGIALLIGCWYCRRSGYRTLWDK
MWART	60 70 80 90 100 110 RRHIGIQKTSRERCSCESPDHQDSRLSSQEKSHQPVVPNAPPAYEKLSSPPPYSPX

FIG. SB

CCAAATCCCTCTCACAAGAATGTGCAGAAG

**TACCTATGGCAATTTAGCTCTCTTGGGTTC AATGCTATTCTAACTAATGACAAGTATTTT** 

**AATTACAGGCGTGAGCCACCACGCCTGGC1** GCCACTATGCCTGACTAATTTTGTAGTTT

CTACTAAACCAGAAATTGGTAGAAGGATT

5/9

GTTGCAATGCATGATACTATCTGTGCCAGA TTGGCTAATAACAAACTAGTCAGGTTTTCG

TATTAAATTGGGAAAACTCCATCAATAAAT GGGGCCATCCAATTTCTCTTTACTTGAAAT GATACITITACAGGITAAGACAAAGGGITG CTATAGCTCTTTTTTTTGAGATGGAGTTT CCTCCTGAGTAGCTGGGATTACAGGCGTGC TCTGCCCGCCTCAGCCTCCCAAAGTGCTGG

600 720 840 960

080

200 320

440

CGCTTTTGTTGCCCAGGCTGGAGTGCAATG

**ACTGGCCTATTTATCTGATCAAGAACAIGT** 

FIG. 3	AGCAGACAGAGTCTCATTAAGGAAGG TGTCCTGTGCCTTGACCCTACAAGATGCCA	ACGGCTGAAGAGGCCGCTGGGATCGGCATC CTGACAGTGATCCTGGGAGTCTTACTGCTC ThraiaGiuGiuaiaAiaGiyiieGiyiie LeuThrVaiiieLeuGiyVaiLeuLeuLeu	CAIGIIGGCACICAAIGIGCCTTAACAAGA AGAIGCCCACAAGAAGGGITTGAICAICGG Hisvaiglythrgincysalaleuthrarg ArgCysProGingluGlyPheAspHisArg	GCTTATGAGAAACTCTCTGCAGAACAGTCA CCACCACCTTATTCACCTTAAGAGCCAGCG	ATCTAATGTTCTCCTTTGGAATGGTGTAGG AAAAATGCAAGCCATCTCTAATAATAAGTC
FIG. 3A FIG. 3B	AGCAGACAGGACTCTCATTAAGGAAGG	ACGGCTGAAGAGGCCGCTGGGATCGGCATCTThrAlaGluGluAlaAlaGlyIle	CATGTTGGCACTCAATGTGCCTTAACAAGA HisVaiGlyThrGinCysAlaLeuThrArg	GCTTATGAGAAACTCTCTGCAGAACAGTCA CCACCACCTTATTCACCT AloTyrGluLysLeuSerAlgGluGinSer ProProProTyrSerPro	ATCTAATGTTCTCCTTTGGAATGGTGTAGG

240

8

360 103

	t c	
1559	<b>AAAAAAAAAAAAAAAAAAAAAAAAA</b>	AAATCATAAAGGATCAGAGATTCTGAAAAA
1439	AGTGCTGATGCCTGTGTACTGCCTTAAATG	<b>AAATAAGTAAAGCTACTATGTACTGCCTT</b>
1319	GCAGTCTAATTACATTTCACTTCAAGGCTC	GGATCCTATATCTTAGGTAAGACATATAAC
1199	GGCTGGTCTCAAACTCCTGACCTCAGGTGA	AGTAGAGGGGGTTTCTCCATGTTGGTCA
107	<b>TCCCAGGTTCAAGCAATTCTCCTGCCTTA</b>	GCGCGATCTTGGCTCACCATAACCTCCGCC
95	<b>ATTATACTACAATAATATATTGTAAAGATC</b>	CAGCAATGTCTCTTTGTGCTCTAAAATTCT
83.	TTGTTCCAGTACTATGGAGTGCTCACAAAG	AACCTTGACCGACATGAACTGTACACAGAA
716	TCTGAGAGACAGAATTCAAGTGGGTATTCT	GGTAATGTTAGTAAATCCATGGTGTTATTT
590	GTACTAATCATGTGAGGAAATGATGAGAAA	AGTGTTAAAATTTTAGTAGGTCCGCTAGCA
****		
47	CTCACACTTTTGCTTGAATTTAATACAGAC	AGACACCTGAGACATGCTGAAATTATTTCT
0	CysGluProValValProAsnAlaProPro	AspSerLysValSerLeuGinGluLysAsn
35	TGTGAACCTGTGGTTCCCAATGCTCCACCT	
ò	GlyTyrArgAldLeuMetAspLysSerLeu	11eGlyCysTrpTyrCysArgArgArgAsn
23	GGATACAGAGCCTTGATGGATAAAAGTCTT	ATCGGCTGTTGGTATTGTAGAAGACGAAAT
7	ProLysLysGlyHisGlyHisSerTyrThr	ArgGluAspAlaHisPhelleTyrGlyTyr
····	CCCAAGAAGGGGCACGCCACICIIACACC	AGAGAAGAIGCICACIICAICIAIGGIIAC

7/9

FIG. 4A | FIG. FIG.

MOUSE TRP2

FIG. WGLVGWGLLL GCLGCGILLR ARAGFPRVCM TLDGVLNKEC CPPLGPEATN ICGFLEGRGQ CAEVQIDIRP WSGPYILRNQ DDREQWPRKF FNRTCKCTGN FAGYNCGGCK FGWTGPDCNR KKPAILRRNI HSLTAQEREQ FLGALDLAKK SIHPDYVITT QHWLGLLGPN GTQPQIANCS VYDFFVWLHY YSVRDTLLGP GRPYKAIDFS HOGPAFVTWH RYHLLWLERE LORLTGNESF ALPYWNFATG GTYEGLLRRN KVGRNNEKLP TLKNVQDCLS LQKFDSPPFF QNSTFSFRNA LGYNYAVDLS EEEAPVWSTT LGVVIGILGA FVLLLGLLAF LQYRRLRKGY KNECDVCTDD WLGAARQDDP TLISRNSRFS TWEIVCDSLD DYNRRVTLCN LEGFOKADGT LOSQVMNLHN LAHSFLNGTN ALPHSAANDP VFVVLHSFTD AIFDEWLKRN NPSTDAWPQE LAPIGHNRMY NMVPFFPPVT NEELFLTAEQ APLMETGLSS KRYTEEA 101 201 251 351 401 451 501 51 301


# HUMAN TRP2

MSPLWWGFLL SCLGCKILPG AGGGFPRVCM TVDSLVNKEC CPRLGAESAN VCGSQQGRGQ CTEVRADIRP WSGPYILRNQ DDRELWPRKF FHRTCKCTGN FAGYNCGDCK FGWTGPNCER KKPPVIRQNI HSLSPQEREQ FLGALDLAKK RVHPDYVITT QHWLGLLGPN GTQPQFANCS VYDFFVWLHY YSVRDTLLGP GRPYRAIDFS HOGPAFYTWH RYHLLCLERD LORLIGNESF ALPYWNFATG RNECDVCTDQ LFGAARPDDP TLISRNSRFS SWETVCDSLD DYNHLVTLCN GTYEGLLRRN QMGRNSMKLP TLKDIRDCLS LQKFDNPPFF QNSTFSFRNA LEGFDKADGT LDSQVMSLHN LVHSFLNGTN ALPHSAANDP IFVVLHSFTD AIFDEWMKRF NPPADAWPQE LAPIGHNRMY NMVPFFPPVT NEELFLTSDQ LGYSYAIDLP VSVEETPGWP TTLLVVMGTL VALVGLFVLL AFLQYRRLRK GYTPLMETHL SSKRYTEEA 351 10 251 151 201 401 451 301 501

FIG. 4

WO 99/46988

Assay of CTLs Generated From
Normal Donor PBL With Ad-GP100Infected Dendritic Cells
(Targets=T2 Cells Pulsed with GP100F9 Peptide)



Effector:Target Ratio

FIG. 5

RECTIFIED SHEET (RULE 91)

### SEQUENCE LISTING

- <110> Nicolette, Charles A.
   Genzyme Corporation
- <120> COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC VACCINATION
- <130> 159792001040
- <140> Unassigned
- <141> 1999-03-19
- <150> 60/078,890
- <151> 1998-03-20
- <160> 17
- <170> Patentin Ver. 2.0
- <210> 1
- <211> 662
- <212> PRT
- <213> Homo sapiens
- <400> 1
- Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly
  1 10 15
- Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp 20 25 30
- Leu Gly Val Ser Arg Gin Leu Arg Thr Lys Ala Trp Asn Arg Gin Leu 35 40
- Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly 50 55
- Gin Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu lie Gly Ala 65 70 75
- Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val 85 90 95
- Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly 100 105 110
- Ser Gln Val Trp Gly Gly Gln Pro Vai Tyr Pro Gln Glu Thr Asp Asp 115 120 125
- Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser 130 135 140
- Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp 145 150 155 160
- Gin Val Leu Gly Gly Pro Val Ser Gly Leu Ser Ile Gly Thr Gly Arg 165 170 175
- Ala Met Leu Gly Thr His Thr Met Glu Val Thr Val Tyr His Arg Arg 190 185 190

Gly	Ser	Arg 195	Ser	Tyr	Val	Pro	Leu 200	Ala	His	Ser	Ser	Ser 205	Ala	Phe	Thr
Ile	Thr 210	Asp	Gln	Val	Pro	Phe 215	Ser	Val	Ser	Val	Ser 220	Gln	ieu	Arg	Ala
Leu 225	Asp	Gly	Gly	Asn	Lys 230	His	Phe	Lau	Arg	Asn 235	Gln	Pro	Leu	Thr	Phe 240
Ala	Leu	Gln	Leu	His 245	Asp	Pro	Ser	Gly	Tyr 250	Leu	Ala	Glu	Ala	Asp 255	Leu
Ser	Tyr	Thr	Trp 260	Asp	Phe	Gly	Asp	Ser 265	Ser	Gly	Thr	Leu	Ile 270	Ser	Arg
Ala	Leu	Val 275	Val	Thr	His	Thr	Tyr 280	Leu	Glu	Pro	Gly	Pro 285	Val	Thr	Ala
Gln	Val 290	Val	Leu	Gla	Ala	Ala 295	Ile	Pro	Leu	Thr	Ser 300	Cys	Gly	Ser	Ser
Pro 305	Val	Pro	Gly	The	Thr 310	Asp	Gly	His	Arg	Pro 315	Thr	Ala	Glu	Ala	320 320
Asn	Thr	Thr	Ala	Gly 325	Gln	Val.	Pro	Thr	Thr 330	Glu	Val	Val	Gly	Thr 335	Thr
Pro	Gly	Gln	Ala 340	Pro	Thr	Ala	Glu	Pro 345	Ser	Gly	Thr	Thr	Ser 350	Val	Gln
Val	Pro	Thr 355	Thr	Glu	Val	Ile	Ser 360	Thr	Ala	Pro	Val	Gla 365	Met	Pro	Thr
Ala	Glu 370	Ser	The	Gly	Met	Thr 375	Pro	Glu	Lys	Val	Pro 380	Val	Ser	G1u	Val
Met 385	Gly	Thr	Thr	Leu	Ala 390	Glu	Met	Ser	Thr	Pro 395	Glu	Ala	Thr	Gly	Met 400
Thr	Pro	Ala	Glu	Val 405	Ser	Ile	Val	Val	Leu 410	Ser	Gly	Thr	Thr	Ala 415	Ala
Gln	Val	Thr	Thr 420	Thr	Glu	Trp	Val	Glu 425	Thr	Thr	Ala	Arg	Glu 430	Leu	Pro
Ile	Pro	Glu 435	Pro	Glu	Gly	Pro	Asp 440	Ala	Ser	Ser	Ile	Met 445	Ser	Thr	Glu
Ser	Ile 450	Thr	Gly	Ser	Leu	Gly 455	Pro	Leu	Leu	Asp	Gly 460	Thr	Ala	Thr	Leu
Arg 465	Leu	Val	Lys	Arg	Gln 470	Val	Pro	Leu	Asp	Cys 475	Val	Leu	Tyr	Arg	Tyr 480
Gly	Ser	Phe	Ser	Val 485	Thr	Leu	Asp	Ile	Val 490	Gln	Gly	Ile	Glu	Ser 495	Ala
Glu	Ile	Leu	Gln 500	Ala	Val	Pro	Ser	Gly 505	Glu	Gly	Asp	Ala	Phe 510	Glu	Leu

```
Thr Val Ser Cys Gin Gly Gly Leu Pro Lys Glu Ala Cys Met Glu Ile
Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg Leu Cys Gln Pro Val
Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His Gln Ile Leu Lys Gly
545
                   550
Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu Ala Asp Thr Asn Ser
Leu Ala Val Val Ser Thr Gln Leu Ile Met Pro Gly Gln Glu Ala Gly
           580
Leu Gly Gln Val Pro Leu Ile Val Gly Ile Leu Leu Val Leu Met Ala
                            600
Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp
   610
                      615
Phe Ser Val Pro Gin Leu Pro His Ser Ser Ser His Trp Leu Arg Leu
                   630
                                       635
Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu
               645
                         650
Ser Gly Gln Gln Val Xaa
            660
<210> 2
<211> 4
<212> PRT
<213> Mus musculus
<400> 2
Leu Glu Gly Ser
1
<210> 3
<211> 4
<212> PRT
<213> Mus musculus
<400> 3
Pro Lys Pro Pro
<210> 4
<211> 4
<212> PRT
<213> Mus musculus
<400> 4
Pro Leu Len Pro
```

```
<210> 5
<211> 5
 <212> PRT
<213> Mus musculus
<400> 5
Arg Ala Arg Gly Leu
  1
<210> 6
<211> 23
<212> DNA
<213> Mus musculus
<400> 6
atgccccaag aagacattca ctt
                                                                    23
<210> 7
<211> 295
<212> DNA
<213> Mus musculus
<400> 7
tgqttatccc aggaagggc acagacgctc ctatgtcact gctgaagagg ccgcagggat 60
cggcatccig atcgtggtcc tggggattgc tctgcttatc ggctgctggt actgtagaag 120
acquagtqqa tacaquacct tqatqqacaa auqqcqtcat attqqtattc auusaacctc 180
aagggaaaga tgctcatgtg agagccctga tcaccaggac agccgactgt cttctcaaga 240
gaaatcccat cagecogtgg ticoccaacge teogeetgee tatgagaage totet
                                                                   295
<210> 8
<211> 24
<212> DNA
<213> Mus musculus
<400> 8
teacegooac ettatteace etga
                                                                   24
<210> 9
<211> 357
<212> DNA
<213> Homo sapiens
<400> 9
atgecaagag aagatgetea etteatetat ggttaceeca agaaggggea eggecaetet 60
tacaccaegg etgaagagge egetgggate ggeateetga eagtgateet gggagtetta 120
ctgctcatcg gergttggra ttgtagaaga cgaaatggat acagageett gatggataaa 180
agtottoatg tiggoactos atgigootta acaagaagat goodacaaga agggittgat 240
categggaca geaaagtgto tetteaagag aaaaaetgtg aacetgtggt teecaatget 300
```

ccacciques atgagaaact ctctgcagaa cagicaccac caccitatto accitaa 357

<210> 10

<211> 8

<212> PRT

<213> Mus musculus

<400> 10

Mat Pro Gln Glu Asp Ile His Phe 1 5

<210> 11

<211> 98

<212> PRT

<213> Mus musculus

<400> 11

GLy Tyr Pro Arg Lys Gly His Arg Arg Ser Tyr Val Thr Ala Glu Glu 1 15

Ala Ala Gly Ile Gly Ile Leu Ile Val Val Leu Gly Ile Ala Leu Leu 20 25 30

The Gly Cys Trp Tyr Cys Arg Arg Arg Ser Gly Tyr Arg Thr Leu Met 35 40

Asp Lys Arg Arg His Ile Gly Ile Gln Lys Thr Ser Arg Glu Arg Cys 50 55

Ser Cys Glu Ser Pro Asp His Gln Asp Ser Arg Leu Ser Ser Gln Glu
65 70 75 80

Lys Ser His Gln Pro Val Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys 85 90 95

Leu Ser

<210> 12

<211> 8

<212> PRT

<213> Mus musculus

<400> 12

Ser Pro Pro Pro Tyr Ser Pro Xaa 1 5

<210> 13

<211>-119

<212> PRT

<213> Homo sapiens

<400> 13

Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly
1 10 15

His Gly His Ser Tyr Thr Thr Ala Glu Glo Ala Ala Gly Ile Gly Ile

20 25 30 Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys 40 Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val Gly Thr Gln Cys Ala Lea Thr Arg Arg Cys Pro Gln Gla Gly Phe Asp His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln Ser 100 105 Pro Pro Pro Tyr Ser Pro Xaa 115 <210> 14 <211> 1559 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (54)..(407) <400> 14 agcagacaga ggactotoat taaggaaggt gtootgtgoo otgaccotac aag atg Met cca aga gaa gat got cad the ato tat ggt tae ood aag aag ggg cac Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly His ggo can not tak acc acg get gas gag god get ggg atd ggd atd etg 152 Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile Leu aca gtg atc ctg gga gtc tta ctg ctc atc ggc tgt tgg tat tgt aga 200 Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys Arg aga cga aat gga tac aga goo tig atg gat aaa agu cit car git ggo Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val Gly 50 act caa tgt gee tta aca aga aga tge eea caa gaa ggg trr gat cat Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp His cgg gac ago aaa gtg tot ott caa gag aaa aac tgt gaa oot gtg gtt Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val Val

occ aat got oca cot got tat gag aaa oto tot goa gaa cag toa oca Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gin Ser Pro

PCT/US99/06034 WO 99/46988

447

100 105 110

cca cot tat tos cot taagagocag ogagacacet gagacatget gaaattattt Pro Pro Tyr Ser Pro 115 ototoacact tingottgas tinastacag acatotaatg biotocttig qastggrata 507 ggaaasatgo aagocatoto taataataag toagtgttaa aattttagta qqtooqoraq 567 cagtactaat catqtqagga aatqatgaga aatattaaat tgggaaaact ccatcaataa 627 atgitigeast geatgatact atetgitgees gaggitastigt tagitaaatee atggitgitat 687 tttotgagag acagaattoa agtgggtatt coggggcoat coaatttoto tttacttoaa 747 atttqqctaa taacaaacta qtcaqqtttt cqaaccttqa ccqacatqaa ctqtacacaq 807 aattgttoca gtactatgga gtgotcacaa aggatacttt tacaggttaa gacaaagggt 867 tgactggeet atttatetga teaagaacat gteageaatg tetetttgtg etetaaaatt 927 ctattatact acaataatat attgtaaaga tootatagot otttttttt gagatggagt 987 ttogettttg ttgcccagge tggagtgeaa tggcgcgate ttggctcace ataacetccg 1047 coroccaggi reaagcaatt eteetgeett ageereetga gtagerggga ttacaggegt 1107 gegecactat geotgactaa tittgtaqtt tiagtagaga eggggettet eeatgttggt 1167 caggotggto toaaactoot gacctcaggt gatotgooog cotcagooto ccaaagtgot 1227 ggaattacag gogtgagoca coacgootgg otggatocta tatottaggt aagacatata 1287 acgcaqtota attacattto acttoaaggo toaatgotat totaactaat gacaaggatt 1347 ttotactada ccagasatty gragaaggat trasataagt asaagctact atgtactgcc 1407 ttagtgotga tgootgtgta otgoottaaa tgtacotatg goaatttago totottgggt 1467 toccaaatoo ototcacaag aatgtgcaga agaaatoata aaggatcaga gattotgaaa 1527 asasasasa sasasasas aasasasaa aa

<210> 15

<211> 118

<212> PRT

<213> Homo sapiens

<400> 15

Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly

His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile

Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys

Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val

50 55 60

Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp 65 70 75 80

His Arg Asp Ser Lys Val Ser Leu Gin Glu Lys Asn Cys Glu Pro Val 85 90 95

Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gin Ser 100 105

Pro Pro Pro Tyr Ser Pro 115

<210> 16

<211> 517

<212> PRT

<213> Mus Musculus

<400> 16

Met Gly Leu Val Gly Trp Gly Leu Leu Clu Gly Cys Leu Gly Cys Gly
1 5 10

Ile Leu Arg Ala Arg Ala Gln Phe Pro Arg Val Cys Met Thr Leu 20 25 30

Asp Gly Vai Leu Asn Lys Glu Cys Cys Pro Pro Leu Gly Pro Glu Ala 35 40 45

Thr Asn Ile Cys Gly Phe Leu Giu Gly Arg Gly Gln Cys Ala Glo Val 50 55 60

Gln Thr Asp Thr Arg Pro Trp Ser Gly Pro Tyr Ile Leu Arg Asn Gln
65 70 75 80

Asp Asp Arg Glu Gln Trp Pro Arg Lys Phe Phe Asn Arg Thr Cys Lys 85 90 95

Cys Thr Gly Asn Phe Ala Gly Tyr Asn Cys Gly Gly Cys Lys Phe Gly 100 105 110

Trp Thr Gly Pro Asp Cys Asn Arg Lys Lys Pro Ala Ile Leu Arg Arg 115 120 125

Asn Ile His Ser Leu Thr Ala Gln Glu Arg Glu Gln Phe Leu Gly Ala 130 135 140

Leu Asp Leu Ala Lys Lys Ser Ile His Pro Asp Tyr Val Ile Thr Thr 145 150 155

Gln His Trp Leu Gly Leu Leu Gly Pro Asn Gly Thr Gln Pro Gln Ile 165 170 175

Ala Asn Cys Ser Val Tyr Asp Phe Phe Val Trp Leu His Tyr Tyr Ser 180 185 190

Val Arg Asp Thr Leu Leu Gly Pro Gly Arg Pro Tyr Lys Ala Ile Asp 195 200 205

Phe Ser His Gln Gly Pro Ala Phe Val Thr Trp His Arg Tyr His Leu

210 215 220

Leu Trp Leu Glu Arg Glu Leu Gln Arg Leu Thr Gly Asn Glu Ser Phe 225 230 235 240

Ala Leu Pro Tyr Trp Asn Phe Ala Thr Gly Lys Asn Glu Cys Asp Val 245 250

Cys Thr Asp Asp Trp Leu Gly Ala Ala Arg Gln Asp Asp Pro Thr Leu 260 265 270

Ile Ser Arg Asn Ser Arg Phe Ser Thr Trp Glu Ile Val Cys Asp Ser 275 280 235

Leu Asp Asp Tyr Asn Arg Arg Val Thr Leu Cys Asn Gly Thr Tyr Glu 290 295 300

Gly Leu Leu Arg Arg Asn Lys Val Gly Arg Asn Asn Glu Lys Leu Pro 305 310 315 320

Thr Leu Lys Asn Val Gln Asp Cys Leu Ser Leu Gln Lys Phe Asp Ser 325 330 335

Pro Pro Phe Phe Glm Asn Ser Thr Phe Ser Phe Arg Asn Ala Leu Glu 340 345 350

Gly Phe Asp Lys Ala Asp Gly Thr Leu Asp Ser Gln Val Met Asn Leu 355 360

His Asn Leu Ala His Ser Phe Leu Asn Gly Thr Asn Ala Leu Pro His 370 380

Ser Ala Ala Asn Asp Pro Val Phe Val Val Leu His Ser Phe Thr Asp 385 390 395 400

Ala Ile Phe Asp Glu Trp Leu Lys Arg Asn Asn Pro Ser Thr Asp Ala 405 410 415

Trp Pro Gln Glu Leu Ala Pro Ile Gly His Asn Arg Met Tyr Asn Met 420 425 430

Val Pro Phe Phe Pro Pro Val Thr Asn Glu Glu Leu Phe Leu Thr Ala 435 440 445

Glu Gin Leu Gly Tyr Asn Tyr Ala Val Asp Leu Ser Glu Glu Glu Ala 450 455 460

Pro Val Trp Ser Thr Thr Leu Ser Val Val Ile Gly Ile Leu Gly Ala
465 470 475 480

Phe Val Leu Leu Gly Leu Leu Ala Phe Leu Gln Tyr Arg Arg Leu 495 495

Arg Lys Gly Tyr Ala Pro Leu Met Glu Thr Gly Leu Ser Ser Lys Arg 500 505 510

Tyr Thr Glu Glu Ala 515

<210> 17

<211> 519

<212> PRT

<213> Homo sapiens

<400> 17

Met Ser Pro Leu Trp Trp Gly Phe Leu Leu Ser Cys Leu Gly Cys Lys
1 5 10

Ile Leu Pro Gly Ala Gln Gly Gln Fhe Pro Arg Val Cys Met Thr Val 20 25 30

Asp Ser Leu Val Asn Lys Glu Cys Cys Pro Arg Leu Gly Ala Glu Ser 35 40 45

Ala Asn Val Cys Gly Ser Gln Gln Gly Arg Gly Gln Cys Thr Glu Val 50 55 60

Arg Ala Asp Thr Arg Pro Trp Ser Gly Pro Tyr Ile Leu Arg Asn Gln 65 70 75 80

Asp Asp Arg Glu Leu Trp Pro Arg Lys Phe Phe His Arg Thr Cys Lys 85 90

Cys Thr Gly Asn Phe Ala Gly Tyr Asn Cys Gly Asp Cys Lys Phe Gly 100 105 110

Trp Thr Gly Pro Asn Cys Glu Arg Lys Lys Pro Pro Val Ile Arg Gln 115 120 125

Asn Ile His Ser Leu Ser Pro Gin Glu Arg Glu Gln Phe Leu Gly Ala 130 135 140

Leu Asp Leu Ala Lys Lys Arg Val His Pro Asp Tyr Val Ile Thr Thr 145 150 155 160

Gln His Trp Leu Gly Leu Leu Gly Pro Asn Gly Thr Gln Pro Gln Phe 165 170 175

Ala Asn Cys Ser Val Tyr Asp Phe Phe Val Trp Leu His Tyr Tyr Ser 180 185 190

Val Arg Asp Thr Leu Leu Gly Pro Gly Arg Pro Tyr Arg Ala Ile Asp 195 200 205

Phe Ser His Gln Gly Pro Ala Phe Val Thr Trp His Arg Tyr His Leu 210 215 220

Leu Cys Leu Glu Arg Asp Leu Glo Arg Leu Ile Gly Ash Glu Ser Phe 225 230 235 240

Ala Leu Pro Tyr Trp Asn Phe Ala Thr Gly Arg Asn Glu Cys Asp Val 245 250 255

Cys Thr Asp Gln Leu Phe Gly Ala Ala Arg Pro Asp Asp Pro Thr Leu 260 265 270

The Ser Arg Asn Ser Arg Phe Ser Ser Trp Glu Thr Val Cys Asp Ser 275 280 285

Leu Asp Asp Tyr Asn His Leu Val Thr Leu Cys Asn Gly Thr Tyr Glu 290 295 300

Gly 305	Leu	Leu	Arg	Ärg	Asn 310	Gln	Met	Gly	Arg	Asn 315	Ser	Met	Lys	Leu	Pro 320
Thr	Leu	Lys	Asp	Ile 325	Arg	Asp	Cys	Leu	Ser 330	Leu	Gln	Lys	Phe	Asp 335	Asn
Pro	Pro	Phe	Phe 340	Gin	Asn	Ser	Thr	Phe 345	Ser	Phe	Arg	Äsn	Ala 350	Leu	Glu
Gly	Phe	Asp 355	Lys	Ala	Asp	Gly	Thr 360	Leu	Asp	Ser	Gin	Val 365	Met	Ser	Leu
Ris	Asn 370	Leu	Val	His	Ser	Phe 375	Leu	Asn	Gly	Thr	Asn 380	Ala	Leu	Pro	His
Ser 385	Ala	Ala	Asn	Asp	Pro 390	Ile	Phe	Väl	Va1	Leu 395	His	Ser	Phe	Thr	Asp 400
Ala	Ile	Phe	qzA	Glu 405	Trp	Met	Lys	Arg	Phe 410	Asn	Pro	Pro	Ala	Asp 415	Ala
Trp	Pro	Gln	Glu 420	Leu	Ala	Pro	Ile	Gly 425	His	Asn	Arg	Met	Tyr 430	Asn	Met
Val	Pro	Phe 435	Phe	Pro	Pro	Val.	Thr 440	Asn	Glu	Glu	Leu	Phe 445	Leu	The	Ser
Asp	Gln 450	Leu	Gly	Tyr	Ser	Tyr 455	Ala	Ile	Asp	Leu	Pro 460	Va1	Ser	Val	Glu
Glu 465	Thr	Pro	Gly	Trp	Pro 470	Thr	Thr	Leu	Leu	Val 475	Val	Met	Gly	Thr	Leu 480
Val	Ala	Leu	Val	Gly 485	Leu	Phe	Val	Leu	Leu 490	Ala	Phe	Leu	Gln	Tyr 495	Arg
Arg	Leu	Arg	Lys 500	Gly	Tyr	Thr	Pro	Leu 505	Met	Gla	Thr	His	Leu 510	Ser	Ser
Lys	Arg	Tyr 515	Thr	Glu	Glu	Ala									

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/06034

,	***************************************		
₹	SSIFICATION OF SUBJECT MATTER		
IPC(6) US CL	:Please See Extra Sheet. :Please See Extra Sheet.		
	to International Patent Classification (IPC) or to both	national classification and IPC	
	LDS SEARCHED		
<b>}</b>	locumentation searched (classification system follow	ed by dissification sumbales	
ĺ		• •	
V.5.	424/184.1, 277.1, 287.1, 93.2, 93.71; 435/372, 373;	314/2, 44; 330/330, 800, 827, 828; 538/.	23. E. 23.3
Documenta	tion searched other than minimum documentation to ti	no extent that such documents are included	in the fields soonhed
			. We words scatomos
Electronic o	fata base consulted during the international search (s	same of data base and, where practicable	, search terms used)
<b></b>	medicine index, APS, WEST	•	,
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.
A,P	LIU, M. Transfected human dendrition	cells as cancer vaccines. Nat.	1-23
	Biotech. April 1988, Vol. 16, pages	335-336, see entire document.	
A	DONNELLY, J.J. et al. DNA vaco		1-23
	1997, Vol. 15, pages 617-648, see en	tire document.	
A, P	PARDOLL, D.M. Cancer vaccines.	Nature Medicine. May 1998,	1-23
	Vol. 4, No.5(suppl.), pages 525-531,	see entire document.	
		ž	
		and the same of th	
		To de la constante de la const	
		and the second s	
X Furth	er documents are listed in the continuation of Box C	See patent family annex.	
• Spe	orial rategories of cised documents:	"T" later document published after the inte	roational filing date or priority
	ouncest defining the general state of the set which is and considered be of particular relevance	date and not in condict with the appli the principle or theory underlying the	
	lier document published on or after the international filing date	"X" document of particular relevance; the	: claimed divention canon be
	rument which may throw doubts on printity claim(s) or which a	considered movel or cannot be consider when the document is taken alone	red to involve an inventive step
cita	ed to establish the publication date of another citation or other coal reason (as specificil)	*Y* document of particular relevance; the	claimed invention cannor be
	sument referring to so cost disclosure, use, exhibition or other	evistaceta na evinenti or benebizano doste tatto econ no esto dive banedano	stop when the document is
me	ans	penult applicate to a believe theighed in fi	to art
	rument published prior to the international filing data but later than priority data claimed	'&' document mention of the same patent	family
Date of the	actual completion of the international search	Date of mailing of the international sea	rch report
26 8 535	1900	03 AUG 1999	
29 JUNE	1377	<b>56</b> A00 133	7
	nailing address of the ISA/US	Authorized offices	
Box PCT	ner of Patents and Trademarks	F PIERRE VANDERVEGT	ice for
	t, D.C. 20231	A LIDARE VAROUR VOUL	yor
Facsimile N	o. (703) 305-3230	Telephone No. (703) 308-0196	1

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/06034

			*
C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant	passages	Relevant to claim No
x	BOCZKOWSKI, D. et al. Dendritic cells pulsed with RN potent antigen-presenting cells in vitro and in vivo. J. Ex 01 August 1996, Vol. 184, No. 2, pages 465-472, see ent document, abstract in particular.	cp. Med.	1-3, 7-10, 14-17, 20, 22
X	US 5,679,647 A (CARSON et al) 21 October 1997, see e document.	entire	1-3, 13, 20-23
X, P  Y, P	US 5,844,075 A (KAWAKAMI et al) 01 December 1998 entire document.	, see	1, 13, 20, 22-23  2-12, 14-19, 21
		to minimize de la companya de la com	
		теттургойдары управления	
		in the second se	

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/06034

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):
A01N 37/18, 43/04, 63/00; A61K 31/70, 35/12, 35/36, 39/00; C12N 5/02, 5/06; C07K 1/00; C07H 21/02, 21/04
A. CLASSIFICATION OF SUBJECT MATTER: US CL :
424/184.1, 277.1, 287.1, 93.2, 93.71; 435/372, 373; 514/2, 44; 530/350, 806, 827, 828; 536/23.1, 23.5

Form PCT/ISA/210 (extra sheet)(July 1992)\*